Abstract 919P
Background
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) is a non-invasive imaging modality. This study aimed to investigate the effects of radiometric parameters and clinical characteristics of 18F-FDG PET-CT on the prognosis of patients with nasopharyngeal carcinoma (NPC).
Methods
A total of 801 patients with metastatic NPC were enrolled between 2016 and 2020, and all participants underwent 18F-FDG PET/CT before treatment. We assessed the following 18F-FDG PET parameters: standardized uptake value (SUV), SUV-avg (average), SUV-peak (maximum), and total lesion glycolysis (TLG) of the primary tumor and regional lymph nodes. We used multivariate Cox proportional hazards models and multiple machine learning techniques to identify independent predictors of survival based on radiomic parameters and patient clinical characteristics. After selecting the features, we established prognosis models using a COX stepwise regression model. Finally, we performed internal validation, and a nomogram was created for NPC comprehensive diagnosis.
Results
In this study, we developed a stable and robust model incorporating five independent prognostic features based on COX regression. The area under the curve (AUC) of the model was 0.75 (95% CI = 0.52–0.97) at 1 year, 0.80 (95% CI = 0.71–0.89) at 3 years, and 0.86 (95% CI = 0.78–0.94) at 5 years. The AUC at 3 years and 5 years were calculated as 0.7276 and 0.7242, respectively. The model was validated using receiver operating characteristic (ROC), consistency index, and multivariate analysis, which showed high accuracy and consistent performance. Moreover, patients in the low-risk score group exhibited significantly better outcomes than those in the high-risk score group (P < 0.001).
Conclusions
Our findings suggest that age, SUV-Tmax, SUV-Tavg, SUV-Tpeak, and TLG-T are valuable parameters for predicting long-term survival in patients with NPC. The nomogram based on metabolic parameters combined with other variables showed good prognostic accuracy in predicting NPC prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12